{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:19:28Z","timestamp":1789885168929,"version":"4.0.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bone marrow mesenchymal stromal cells (BM-MSCs) have been characterized and used in many clinical studies based on their immunomodulatory and regenerative properties. We have recently reported the benefit of autologous MSC systemic therapy in the treatment of type 1 diabetes mellitus (T1D). Compared with allogeneic cells, use of autologous products reduces the risk of eliciting undesired complications in the recipient, including rejection, immunization, and transmission of viruses and prions; however, comparable potency of autologous cells is required for this treatment approach to remain feasible. To date, no analysis has been reported that phenotypically and functionally characterizes MSCs derived from newly diagnosed and late-stage T1D donors in vitro with respect to their suitability for systemic immunotherapy. In this study, we used gene array in combination with functional in vitro assays to address these questions. MSCs from T1D donors and healthy controls were expanded from BM aspirates. BM mononuclear cell counts and growth kinetics were comparable between the groups, with equivalent colony-forming unit-fibroblast capacity. Gene microarrays demonstrated differential gene expression between healthy and late-stage T1D donors in relation to cytokine secretion, immunomodulatory activity, and wound healing potential. Despite transcriptional differences, T1D MSCs did not demonstrate a significant difference from healthy controls in immunosuppressive activity, migratory capacity, or hemocompatibility. We conclude that despite differential gene expression, expanded MSCs from T1D donors are phenotypically and functionally similar to healthy control MSCs with regard to their immunomodulatory and migratory potential, indicating their suitability for use in autologous systemic therapy.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>The potential for mesenchymal stromal cells (MSCs) as a cell-based therapy in the treatment of immunologic disorders has been well established. Recent studies reported the clinical potential for autologous MSCs as a systemic therapy in the treatment of type I diabetes mellitus (T1D). The current study compared the genotypic and phenotypic profiles of bone marrow-derived MSCs from T1D and healthy donors as autologous (compared with allogeneic) therapy provides distinct advantages, such as reduced risk of immune reaction and transmission of infectious agents. The findings of the current study demonstrate that despite moderate differences in T1D MSCs at the gene level, these cells can be expanded in culture to an extent corresponding to that of MSCs derived from healthy donors. No functional difference in terms of immunosuppressive activity, blood compatibility, or migratory capacity was evident between the groups. The study findings also show that autologous MSC therapy holds promise as a T1D treatment and should be evaluated further in clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5966\/sctm.2015-0272","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T06:52:12Z","timestamp":1468479132000},"page":"1485-1495","source":"Crossref","is-referenced-by-count":44,"title":["Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro"],"prefix":"10.1093","volume":"5","author":[{"given":"Lindsay C.","family":"Davies","sequence":"first","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Alm","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Heldring","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Moll","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gavin","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Batsis","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qian","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Sigvardsson","sequence":"additional","affiliation":[{"name":"Institution for Clinical and Experimental Medicine, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E.","family":"Kyllonen","sequence":"additional","affiliation":[{"name":"Division of Transplantation, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaija T.","family":"Salmela","sequence":"additional","affiliation":[{"name":"Division of Transplantation, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Ola","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Medical Cell Biology, Uppsala University, Sweden"},{"name":"Department of Medical Sciences, Uppsala University, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[{"name":"Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Le Blanc","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Divisions of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2021122705122982000_R1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1101\/cshperspect.a007641","article-title":"The pathogenesis and natural history of type 1 diabetes","volume":"2","author":"Atkinson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021122705122982000_R2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2009.21","article-title":"The role of inflammation in insulitis and beta-cell loss in type 1 diabetes","volume":"5","author":"Eizirik","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"2021122705122982000_R3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187153012800493530","article-title":"Bone marrow microenvironment: A newly recognized target for diabetes-induced cellular damage","volume":"12","author":"Mangialardi","year":"2012","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2021122705122982000_R4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5966\/sctm.2012-0116","article-title":"Stem cell therapy to cure type 1 diabetes: From hype to hope","volume":"2","author":"Chhabra","year":"2013","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122705122982000_R5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trre.2012.11.003","article-title":"Potential role of mesenchymal stromal cells in pancreatic islet transplantation","volume":"27","author":"Hematti","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"2021122705122982000_R6","doi-asserted-by":"crossref","first-page":"17438","DOI":"10.1073\/pnas.0608249103","article-title":"Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD\/scid mice","volume":"103","author":"Lee","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122705122982000_R7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1634\/stemcells.2007-0267","article-title":"Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes","volume":"26","author":"Urb\u00e1n","year":"2008","journal-title":"Stem Cells"},{"key":"2021122705122982000_R8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3727\/096368912X647162","article-title":"Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice","volume":"22","author":"Gabr","year":"2013","journal-title":"Cell Transplant"},{"key":"2021122705122982000_R9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3727\/096368911X603611","article-title":"Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and \u03b2-cell differentiation in streptozocin-induced diabetic mice","volume":"21","author":"Ho","year":"2012","journal-title":"Cell Transplant"},{"key":"2021122705122982000_R10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/stem.1111","article-title":"Are therapeutic human mesenchymal stromal cells compatible with human blood?","volume":"30","author":"Moll","year":"2012","journal-title":"Stem Cells"},{"key":"2021122705122982000_R11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s00125-014-3262-4","article-title":"Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes","volume":"57","author":"Favaro","year":"2014","journal-title":"Diabetologia"},{"key":"2021122705122982000_R12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2014.41","article-title":"MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease","volume":"28","author":"Kordelas","year":"2014","journal-title":"Leukemia"},{"key":"2021122705122982000_R13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/14653249.2010.518608","article-title":"Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro","volume":"13","author":"Jung","year":"2011","journal-title":"Cytotherapy"},{"key":"2021122705122982000_R14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/TP.0b013e3181c7dc99","article-title":"Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation","volume":"89","author":"Park","year":"2010","journal-title":"Transplantation"},{"key":"2021122705122982000_R15","doi-asserted-by":"crossref","first-page":"a007807","DOI":"10.1101\/cshperspect.a007807","article-title":"Breakdown in peripheral tolerance in type 1 diabetes in mice and humans","volume":"2","author":"Jeker","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021122705122982000_R16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4049\/jimmunol.180.3.1929","article-title":"Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics","volume":"180","author":"Wang","year":"2008","journal-title":"J Immunol"},{"key":"2021122705122982000_R17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes"},{"key":"2021122705122982000_R18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/dc15-0171","article-title":"Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: A pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion","volume":"39","author":"Cai","year":"2016","journal-title":"Diabetes Care"},{"key":"2021122705122982000_R19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5966\/sctm.2014-0212","article-title":"Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis","volume":"4","author":"Oh","year":"2015","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122705122982000_R20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nep.12338","article-title":"Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: A pilot study","volume":"20","author":"Mudrabettu","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"2021122705122982000_R21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"2021122705122982000_R22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-3083.2003.01176.x","article-title":"Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex","volume":"57","author":"Le Blanc","year":"2003","journal-title":"Scand J Immunol"},{"key":"2021122705122982000_R23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/sj.leu.2404777","article-title":"Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells","volume":"21","author":"Le Blanc","year":"2007","journal-title":"Leukemia"},{"key":"2021122705122982000_R24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/MCB.01287-12","article-title":"Molecular characterization of prospectively isolated multipotent mesenchymal progenitors provides new insight into the cellular identity of mesenchymal stem cells in mouse bone marrow","volume":"33","author":"Qian","year":"2013","journal-title":"Mol Cell Biol"},{"key":"2021122705122982000_R25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc"},{"key":"2021122705122982000_R26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1089\/scd.2011.0434","article-title":"Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner","volume":"21","author":"Davies","year":"2012","journal-title":"Stem Cells Dev"},{"key":"2021122705122982000_R27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1177\/0022034510377796","article-title":"\u2018Young\u2019 oral fibroblasts are geno\/phenotypically distinct","volume":"89","author":"Enoch","year":"2010","journal-title":"J Dent Res"},{"key":"2021122705122982000_R28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood.V92.5.1661","article-title":"Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation","volume":"92","author":"Nilsson","year":"1998","journal-title":"Blood"},{"key":"2021122705122982000_R29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2337\/diabetes.48.10.1907","article-title":"Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation?","volume":"48","author":"Bennet","year":"1999","journal-title":"Diabetes"},{"key":"2021122705122982000_R30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/TP.0b013e31820ae459","article-title":"The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation","volume":"91","author":"Gustafson","year":"2011","journal-title":"Transplantation"},{"key":"2021122705122982000_R31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4614-4118-2_18","article-title":"Evaluation of the blood compatibility of materials, cells, and tissues: Basic concepts, test models, and practical guidelines","volume":"735","author":"Ekdahl","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"2021122705122982000_R32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbmt.2011.07.023","article-title":"Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy","volume":"18","author":"von Bahr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122705122982000_R33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1464-5491.2006.01773.x","article-title":"The molecular biology of chronic wounds and delayed healing in diabetes","volume":"23","author":"Blakytny","year":"2006","journal-title":"Diabet Med"},{"key":"2021122705122982000_R34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.0022-202X.2004.22319.x","article-title":"Regulation of MAPK activation, AP-1 transcription factor expression and keratinocyte differentiation in wounded fetal skin","volume":"122","author":"Gangnuss","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122705122982000_R35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcb.10309","article-title":"BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells","volume":"87","author":"Fiedler","year":"2002","journal-title":"J Cell Biochem"},{"key":"2021122705122982000_R36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/wrr.12170","article-title":"Identification of a transcriptional signature for the wound healing continuum","volume":"22","author":"Peake","year":"2014","journal-title":"Wound Rep Regen"},{"key":"2021122705122982000_R37","doi-asserted-by":"crossref","first-page":"e48061","DOI":"10.1371\/journal.pone.0048061","article-title":"Promise(s) of mesenchymal stem cells as an in vitro model system to depict pre-diabetic\/diabetic milieu in WNIN\/GR-Ob mutant rats","volume":"7","author":"Madhira","year":"2012","journal-title":"PLoS One"},{"key":"2021122705122982000_R38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","article-title":"Mesenchymal stromal cells: Sensors and switchers of inflammation","volume":"13","author":"Bernardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2021122705122982000_R39","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1089\/scd.2013.0559","article-title":"Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1","volume":"23","author":"Deng","year":"2014","journal-title":"Stem Cells Dev"},{"key":"2021122705122982000_R40","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"Meisel","year":"2004","journal-title":"Blood"},{"key":"2021122705122982000_R41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3324\/haematol.2012.078055","article-title":"Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6","volume":"98","author":"Melief","year":"2013","journal-title":"Haematologica"},{"key":"2021122705122982000_R42","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.2337\/db13-0896","article-title":"Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity","volume":"62","author":"Acosta","year":"2013","journal-title":"Diabetes"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/11\/1485\/41870071\/stcltm_5_11_1485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/11\/1485\/41870071\/stcltm_5_11_1485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:50:32Z","timestamp":1642560632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/5\/11\/1485-1495\/6397655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,7,13]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2015-0272","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11,1]]},"published":{"date-parts":[[2016,7,13]]}}}